As Pfizer Deal Speeds Up, Aurobindo Pairs Up With AstraZeneca For Branded Generics Play In Emerging Markets
This article was originally published in The Pink Sheet Daily
Executive Summary
India's Aurobindo Pharma is turning out to be a partner of choice for Big Pharma companies that intend to dig aggressively into emerging markets with a branded generics product portfolio.
You may also be interested in...
With Emerging Markets On Radar, AstraZeneca Close To Teaming Up With India's Intas For Sourcing Sterile And Oncology Drugs
MUMBAI - AstraZeneca is days away from signing an agreement with India's Intas Pharmaceuticals for supplies of a large number of generic sterile and oncology products to be sold in emerging markets. The deal will likely cover as many as 45 products to be sold in nine markets, with the scope for expanding the range of products further
AZ Taps India's Torrent to Add Branded Generics in Emerging Markets
LONDON - To extend its reach in emerging markets, AstraZeneca PLC today said it had signed an agreement with India's Torrent Pharmaceuticals Ltd. for the rights to sell 18 undisclosed generic drugs in nine territories
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.